Document ID: FDA-2011-N-0002-0078
Agency: fda
Document Type: Notice
Title: Risk Communication Advisory Committee; Notice of Meeting
Posted Date: 2011-07-22T04:00Z

[Federal Register Volume 76, Number 141 (Friday, July 22, 2011)]
[Notices]
[Pages 44017-44018]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-18507]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2011-N-0002]

Risk Communication Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). The meeting will 
be open to the public.
    Name of Committee: Risk Communication Advisory Committee.
    General Function of the Committee: To provide advice and 
recommendations to the Agency on FDA's regulatory issues.
    Date and Time: The meeting will be held on August 15, 2011, from 8 
a.m. to 5 p.m. and August 16, 2011, from 8 a.m. to 2 p.m.
    Location: FDA White Oak Campus, 10903 New Hampshire Ave., Building 
31 Conference Center, the Great Room (rm. 1503), Silver Spring, MD 
20993-0002. Information regarding special accommodations due to a 
disability, visitor parking, and transportation may be accessed at: 
http://www.fda.gov/AdvisoryCommittees/default.htm; under the heading 
``Resources for You'', click on ``Public Meetings at the FDA White Oak 
Campus.'' Please note that visitors to the White Oak Campus must enter 
through Building 1.
    Contact Person: Lee L. Zwanziger, Office of Policy, Planning and 
Budget, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 
32, rm. 3278, Silver Spring, MD 20993, 301-796-9151, FAX: 301-847-8611, 
e-mail: RCAC@fda.hhs.gov, or FDA Advisory Committee Information Line, 
1-800-741-8138 (301-443-0572 in the Washington, DC area), and follow 
the prompts to the desired center or product area. Please call the 
Information Line for up-to-date information on this meeting. A notice 
in the Federal Register about last minute modifications that impact a 
previously announced advisory committee meeting cannot always be 
published quickly enough to provide timely notice. Therefore, you 
should always check the Agency's Web site and call the appropriate 
advisory committee hot line/phone line to learn about possible 
modifications before coming to the meeting.
    Agenda: On August 15, 2011, the Committee will discuss challenges 
of communicating about evolving methodology in the attribution of 
foodborne illness. Estimating the number of illnesses, 
hospitalizations, and deaths caused by major pathogens is the first 
step in the development of disease prevention strategies. Estimating 
the proportions of these illnesses due to specific food sources (food 
source attribution) is a necessary second step towards identifying the 
sources that cause substantial preventable human illness and measuring 
progress toward public health goals resulting from public health 
interventions applied to those food sources. Consequently, FDA, the 
Centers for Disease Control and Prevention, and the U.S. Department of 
Agriculture/Food Safety Inspection Service have begun a joint 
initiative, called the Interagency Food Safety Analytics Collaboration 
(IFSAC), to improve our collective understanding of source attribution 
of infections to specific foods and settings. While the IFSAC works to 
improve methodology, we are also committed to keeping stakeholders 
informed and engaged, and are seeking advice about how to communicate 
most effectively. On August 16, 2011, the Committee will present 
``Communicating Risks and Benefits: An Evidence-Based User's Guide.'' 
This volume is the result of work, as discussed in previous meetings, 
by current and former members of the Risk Communication Advisory 
Committee.
    FDA intends to make background material available to the public no 
later than 2 business days before the meeting. If FDA is unable to post 
the background material on its Web site prior to the meeting, the 
background material will be made publicly available at the location of 
the advisory committee meeting, and the background material will be 
posted on FDA's Web site after the meeting. Background material is 
available at http://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll down to the appropriate advisory committee link.
    Procedure: Interested persons may present data, information, or 
views, orally or in writing, on issues pending before the committee. 
Written submissions may be made to the contact person on or before 
August 10, 2011. Oral presentations from the public will be scheduled 
between approximately 1 p.m. and 2 p.m. on August 15, 2011, and 10:30 
a.m. and 11:30 a.m. on August 16, 2011. Those individuals interested in 
making formal oral presentations should notify the contact person and 
submit a brief statement of the general nature of the evidence or 
arguments they wish to present, the names and addresses of proposed 
participants, and an indication of the approximate time requested to 
make their presentation on or before August 2, 2011. Time allotted for 
each presentation may be limited. If the number of registrants 
requesting to speak is greater than can be reasonably accommodated 
during the scheduled open public hearing session, FDA may conduct a 
lottery to determine the speakers for the scheduled open public hearing 
session. The contact person will notify interested persons regarding 
their request to speak by August 3, 2011. Interested persons can also 
log on to https://collaboration.fda.gov/rcac/ to hear and see the 
proceedings.
    Persons attending FDA's advisory committee meetings are advised 
that the Agency is not responsible for providing access to electrical 
outlets.
    FDA welcomes the attendance of the public at its advisory committee 
meetings and will make every effort to accommodate persons with 
physical

[[Page 44018]]

disabilities or special needs. If you require special accommodations 
due to a disability, please contact Lee L. Zwanziger at least 7 days in 
advance of the meeting.
    FDA is committed to the orderly conduct of its advisory committee 
meetings. Please visit our Web site at http://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures 
on public conduct during advisory committee meetings.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: July 18, 2011.
Jill Hartzler Warner,
Acting Associate Commissioner for Special Medical Programs.
[FR Doc. 2011-18507 Filed 7-21-11; 8:45 am]
BILLING CODE 4160-01-P